arrow_back Back to App

Ending Double Drug Patents: Lower Prices, Greater Access

This act aims to prevent pharmaceutical companies from misusing patents, which can lead to artificially inflated drug prices. With new rules, generic drugs may enter the market faster, potentially lowering treatment costs for citizens and increasing access to essential medicines. The U.S. Patent Office will also review its procedures to prevent unfair extensions of drug exclusivity.
Key points
Limiting the ability to hold multiple patents for the same drug, which should accelerate the availability of cheaper alternatives.
Pharmaceutical companies will need to prove their patents cover truly distinct inventions to maintain longer exclusivity.
The U.S. Patent Office will review its operations to ensure it does not issue patents that unnecessarily extend drug monopolies.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_890
Sponsor: Rep. Ryan, Patrick [D-NY-18]
Process start date: 2025-01-31
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stopping Pharma’s Ripoffs and Drug Savings For All Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_890.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-01-31.

What are the main provisions?

Key points include:

  • Limiting the ability to hold multiple patents for the same drug, which should accelerate the availability of cheaper alternatives.
  • Pharmaceutical companies will need to prove their patents cover truly distinct inventions to maintain longer exclusivity.
  • The U.S. Patent Office will review its operations to ensure it does not issue patents that unnecessarily extend drug monopolies.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Ryan, Patrick [D-NY-18].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Courts and Law Economy